IQVIA (IQV) Issues FY18 Earnings Guidance

IQVIA (NYSE:IQV) updated its FY18 earnings guidance on Friday. The company provided EPS guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.IQVIA also updated its Q2 guidance to $1.17-1.24 EPS.

A number of equities research analysts recently issued reports on the company. SunTrust Banks reiterated a hold rating and issued a $110.00 price objective on shares of IQVIA in a research report on Monday, January 22nd. Mizuho set a $97.00 price objective on IQVIA and gave the stock a hold rating in a research report on Wednesday, January 24th. Zacks Investment Research upgraded IQVIA from a strong sell rating to a hold rating in a research report on Friday, March 23rd. Royal Bank of Canada set a $118.00 price objective on IQVIA and gave the stock a buy rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase increased their price objective on IQVIA from $115.00 to $120.00 and gave the stock an overweight rating in a research report on Thursday, February 15th. Seven equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. IQVIA currently has an average rating of Buy and a consensus price target of $110.47.

IQVIA opened at $97.83 on Friday, according to Marketbeat Ratings. IQVIA has a twelve month low of $100.50 and a twelve month high of $101.78. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 1.22. The stock has a market cap of $20.53 billion, a price-to-earnings ratio of 22.44, a PEG ratio of 1.66 and a beta of 0.64.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.07. The business had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.42 billion. IQVIA had a return on equity of 13.35% and a net margin of 13.07%. The business’s revenue was up 34.1% compared to the same quarter last year. analysts predict that IQVIA will post 5.06 EPS for the current fiscal year.

In other news, insider James H. Erlinger III sold 10,000 shares of IQVIA stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael J. Evanisko sold 816 shares of IQVIA stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $100.00, for a total value of $81,600.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,527 shares of company stock worth $1,257,834. Company insiders own 6.00% of the company’s stock.

About IQVIA

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Earnings History and Estimates for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply